参考文献/References:
[1] SEER Cancer Statistics Factsheets:Thyroid Cancer[DB/OL].Bethesda(MD):National Cancer Institute[2015-01-06].http://seer.cancer.gov/statfacts/html/thyro.Html.
[2] 陈万青,张思維,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10.
[3] 孙嘉伟,许晓君,蔡秋茂,等.中国甲状腺癌发病趋势分析[J].中国肿瘤,2013,22(9):690-693.
[4] Hundahi SA,Fleming ID,Fremgen AM,et al.A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S.,1985-1995[J].Cancer,1998,83(12):2638-2648.
[5] Brown AP,Greening WP,McCready VR,et al.Radioiodine treat-ment of metastatic thyroid carcinoma:the Royal Marsden Hospital expeiience[J],Br J Radiol,1984,57(676):323-327.
[6] Schlumberger M,Tubiana M,De Vathaire F,et al.Long-term re-sults of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,1986,63(4):960-967.
[7] Ruegemer JJ,Hay ID,Bergstralh EJ,et al.Distant metastases in dif-ferentiated thyroid carcinoma:a multivariate analysis of prognostic variables[J].J Clin Endocrinol Metab,1988,67(3):501-508.
[8] Schlumberger M,Challeton C,De Vathaire F,et al.Radioactive io-dine treatment and external radiotherapy for lung and bone metas-tases from thyroid carcinoma[J].J Nucl Med,1996,37(4):598-605.
[9] Mihailovic J,Stefanovic L,Malesevic M,et al.The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases[J].Thyroid,2009,19(3):227-232.
[10] Pacini F,Cetani F,Miccoli P,et al.Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine[J].World J Surg,1994,18(4):600-604.
[11] Lee J,Soh EY.Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prog-nostic factors[J].Ann Surg,2010,251(1):114-119.
[12] Schlumberger M,Brose M,Elisei R,et al.Definition and manage-ment of radioactive iodine-refractory differentiated thyroid cancer[J].Lancet Diabetes Endocrinol,2014,2(5):356-358.
[13] Sabra MM,Grewal RK,Tala H,et al.Clinical outcomes following empiric radioiodine therapy in patients with structurally identifi-able metastatic follicular cell-derived thyroid carcinoma with nega-tive diagnostic but positive post-therapy 131I whole-body scans[J].Thyroid,2012,22(9):877-883.
[14] Sgouros G,Kolbert KS,Sheikh A,et al.Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-in-ternal dosimetry (3D-ID) software[J].J Nucl Med,2004,45(8):1366-1372.
[15] Robbins RJ,Wan Q,Grewal RK,et al.Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography scanning[J].J Clin En-docrinol Metab,2006,91(2):498-505.
[16] Leboulleux S,El Bez I,Borget I,et al.Post-Radioiodine Treatment Whole Body Scan in the Era of Fluorodesoxyglucose Positron E -mission Tomography for Differentiated Thyroid Carcinoma with ele-vated serum thyroglobulin levels[J/OL].Thyroid,2012[2015-01-06].http://www.ncbi.nlm.nih.gov/pubmed/?term=22667339.[published online ahead of print].
[17] Vaisman F,Tala H,Grewal R,et al.In differentiated thyroid can-cer,an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thy-roglobulin response[J].Thyroid,2011,21(12):1317-1322.
[18] Durante C,Haddy N,Baudin E,et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thy-roid carcinoma:benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab,2006,91(8):2892-2899.
[19] Rubino C,de Vathaire F,Dottorini ME,et al.Second primary ma-lignancies in thyroid cancer patients[J].Br J Cancer,2003,89(9):1638-1644.
[20] Brose MS,Nutting CM,Sherman SI,et al.Rationale and design of decision:a double-blind,randomized,placebo-controlled phase Ⅱ-I trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory,differentiated thyroid cancer[J/OL].BMC Cancer,2011,11:349[2015-01-06].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164634.
[21] Marotta V,Ramundo V,Camera L,et al.Sorafenib in advanced io-dine-refractory differentiated thyroid cancer:efficacy,safety and exploratory analysis of role of serum thyroglobulin and FDG-PET[J].Clin Endocrinol(Oxf),2013,78(5):760-767.
[22] Sherman EJ,Su YB,Lyall A,et al.Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive io-dine-refractory thyroid carcinoma[J].Thyroid,2013,23(5):593-599.
[23] Sacks W,Braunstein GD.Evolving approaches in managing ra-dioactive iodine-refractory differentiated thyroid cancer[J].Endocr Pract,2014,20(3):263-275.
[24] Fassnacht M,Kreissl MC,Weismann D,et al.New targets and ther-apeutic approaches for endocrine malignancies[J].Pharmacol Ther,2009,123(1):117-141.
[25] Vasko VV,Saji M.Molecular mechanisms involved in differentiat-ed thyroid cancer invasion and metastasis.Curr Opin Oncol,2007,19(1):11-17.
[26] Nikiforova MN,Nikiforov YE.Molecular genetics of thyroid can-cer:implications for diagnosis,treatment and prognosis[J].Expert Rev Mol Diagn,2008,8(1):83-95.
[27] Leboulleux S,Bastholt L,Krause T,et al.Vandetanib in locally ad-vanced or metastatic differentiated thyroid cancer:a randomised,double-blind,phase 2 trial[J].Lancet Oncol,2012,13(9):897-905.
[28] Schneider TC,Abdulrahman RM,Corssmit EP,et al.Long-termanalysis of the efficacy and tolerability of sorafenib in advanced ra-dio-iodine refractory differentiated thyroid carcinoma:final results of a phase Ⅱ trial[J].Eur J Endocrinol,2012,167(5):643-650.
[29] Gupta-Abramson V,Troxel AB,Nellore A,et al.Phase Ⅱ trial of so-rafenib in advanced thyroid cancer[J].J Clin Oncol,2008,26(29):4714-4719.
[30] Keefe SM,Troxel AB,Rhee K,et al.Phase Ⅱ trial of sorafenib in patients with advanced thyroid cancer[J/OL].J Clin Oncol,2011,29(suppl):5562[2015-01-06].http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/5562?sid=e9e4a730-7f44-4fc1-9cd9-9704755e7c8a.
[31] Kloos RT,Ringel MD,Knopp MV,et al.Phase Ⅱ trial of sorafenib in metastatic thyroid cancer[J].J Clin Oncol,2009,27(10):1675-1684.
[32] Hoftijzer H,Heemstra KA,Morreau H,et al.Beneficial effects of sorafenib on tumor progression,but not on radioiodine uptake,in patients with differentiated thyroid carcinoma[J].Eur J Endocrinol,2009,161(6):923-931.
[33] Ahmed M,Barbachano Y,Riddell A,et al.Analysis of the efficacy and toxicity of sorafenib in thyroid cancer:a phase Ⅱ study in a UK based population[JJ.Eur J Endocrinol,2011,165(2):315-322.
[34] Capdevila J,Iglesias L,Halperin I,et al.Sorafenib in metastatic thyroid cancer[J].Endocr Relat Cancer,2012,19(2):209-216.
[35] Brose MS,Nutting CM,Jarzab B,et al.Sorafenib in radioactive io-dine-refractory,locally advanced or metastatic differentiated thy-roid cancer:a randomised,double-blind,phase 3 trial[J].Lancet,2014,384(9940):319-328.
[36] Carr LL,Mankoff DA,Goulart BH,et al.Phase Ⅱ study of daily sunitinib in FDG-PET-positive,iodine-refractory differentiated thy-roid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation[J].Clin Cancer Res,2010,16(21):5260-5268.
[37] Cohen EE,Rosen LS,Vokes EE,et al.Axitinib is an active treat-ment for all histologic subtypes of advanced thyroid cancer:results from a phase Ⅱ study[J].J Clin Oncol,2008,26(29):4708-4713.
[38] Cohen EE,Tortorici M,Kim S,et al.A Phase Ⅱ trial of axitinib inpatients with various histologic subtypes of advanced thyroid can-cer:long-term outcomes and pharmacokinetic/pharmacodynamic analyses[J].Cancer Chemother Pharmacol,2014,74(6):1261-1270.
[39] Rosen LS,Kurzrock R,Mulay M,et al.Safety,pharmacokinetics,and efficacy of A M G 706,an oral multikinase inhibitor,in patients with advanced solid tumors[J].J Clin Oncol,2007,25(17):2369-2376.
[40] Sherman SI,Wirth LJ,Droz JP,et al.Motesanib diphosphate in progressive differentiated thyroid cancer[J].N Engl J Med,2008,359(1):31-42.
[41] Bible KC,Suman VJ,Molina JR,et al.Efficacy of pazopanib in pro-gressive,radioiodine-refractory,metastatic differentiated thyroid cancers:results of a phase 2 consortium study[J].Lancet Oncol,2010,11(10):962-972.
[42] Sherman SI,Jarzab B,Cabanillas ME,et al.A phase Ⅱ trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)[J/OL].J Clin Oncol,2011,29(suppl 15):5503[2015-01-06].http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/5503?sid=0d6ff59e-7497-4112-bf1d-8c58dd0b8bd4.
相似文献/References:
[1]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[2]孙昱,符达,刘兴党.卵巢癌循环肿瘤细胞的生物学特性及其临床应用进展[J].国际放射医学核医学杂志,2016,40(1):60.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
Sun Yu,Fu Da,Liu Xingdang.Progress in biological characteristics and clinical application of circulating tumor cells in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):60.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
[3]蒿崑,孙珊珊,赵斌.规范化应用影像学检查对乳腺疾病诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(1):70.[doi:10.3760/cma.j.issn.1673-4114.2016.01.014]
Hao Kun,Sun Shanshan,Zhao Bin.The value of the standard application of medical imaging examination in the diagnosis of breast disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):70.[doi:10.3760/cma.j.issn.1673-4114.2016.01.014]
[4]唐令胜,刘朝晖,李红梅,等.低场磁共振DWI技术与常规MRI扫描对超急性脑梗死的诊断灵敏度的比较[J].国际放射医学核医学杂志,2016,40(3):187.[doi:10.3760/cma.j.issn.1673-4114.2016.03.006]
Tang Lingsheng,Liu Zhaohui,Li Hongmei,et al.Comparison of the diagnostic sensitivity of low-field magnetic resonance diffusion weighted imaging technology and conventional MRI scanning for super acute cerebral infarction[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):187.[doi:10.3760/cma.j.issn.1673-4114.2016.03.006]
[5]刘惠惠,李险峰.放射性心脏损伤诊断和防治的临床研究进展[J].国际放射医学核医学杂志,2016,40(5):374.[doi:10.3760/cma.j.issn.1673-4114.2016.05.008]
Liu Huihui,Li Xianfeng.Clinical research progress in diagnosis,prevention and treatment of radiation-induced heart disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):374.[doi:10.3760/cma.j.issn.1673-4114.2016.05.008]
[6]耿欣,宋其韬,肖世骞,等.CT技术诊断下肢动脉硬化闭塞症的应用进展[J].国际放射医学核医学杂志,2015,39(6):501.[doi:10.3760/cma.j.issn.1673-4114.2015.06.014]
Geng Xin,Song Qitao,Xiao Shiqian,et al.Technology progress of computed tomography in the diagnosis for lower extremity arteriosclerosis obliterans[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):501.[doi:10.3760/cma.j.issn.1673-4114.2015.06.014]
[7]周文兰,吴湖炳,韩彦江,等.18F-FDG PET/CT对骨骼孤立性高代谢病灶的初步诊断价值[J].国际放射医学核医学杂志,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
Zhou Wenlan,Wu Hubing,Han Yanjiang,et al.Preliminary study of 18F-FDG PET/CT in the diagnosis of solitary hypermetabolic lesion of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
[8]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[9]黄静,袁卫红.骨关节炎诊治方法新进展[J].国际放射医学核医学杂志,2014,38(1):64.[doi:10.3760/cma.j.issn 1673-4114.2014.01.013]
Huang Jing,Yuan Weihong.The new progress of osteoarthritis treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):64.[doi:10.3760/cma.j.issn 1673-4114.2014.01.013]
[10]姚小芹,王辉.BRAPV600E基因突变在甲状腺癌中的临床应用研究进展[J].国际放射医学核医学杂志,2012,36(2):84.[doi:10.3760/cma.j.issn.1673-4114.2012.02.006]
YAO Xiao-qin,WANG Hui.Advances in clinical utility of BRAFV600E mutation in thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):84.[doi:10.3760/cma.j.issn.1673-4114.2012.02.006]